IMUX Earnings & Financial Statements
Immunic, Inc.
$7.64
-$0.19(-2.37%)
33
Overall
60
Value
27
Tech
13
Quality
Market Cap
$106.70M
Volume
68.18K
52W Range
$5.06 - $17.43
Target Price
$43.09
IMUX earnings and financial statements: Immunic, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
IMUX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$103.23M | -$98.05M | -$99.22M | -$119.49M | -$91.67M |
| EBITDA | -$97.00M | -$100.37M | -$93.50M | -$86.44M | -$91.58M |
| Net income | -$97.17M | -$100.51M | -$93.61M | -$120.41M | -$92.94M |
| EPS (diluted) | $-0.62 | $-10.00 | $-21.10 | $-37.80 | $-39.30 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $24.05M | $40.87M | $54.30M | $127.75M | $139.10M |
| Total liabilities | $30.73M | $22.44M | $25.37M | $14.07M | $11.98M |
| Shareholders’ equity | -$6.67M | $18.43M | $28.93M | $113.68M | $127.11M |
| Cash and equivalents | $15.50M | $35.67M | $46.67M | $106.75M | $86.86M |
| Long-term debt | $107.0K | $264.0K | $639.0K | $992.0K | $584.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$85.81M | -$84.77M | -$70.83M | -$65.14M | -$83.23M |
| Capital expenditure | -$161.0K | -$264.0K | -$334.0K | -$112.0K | -$67.0K |
| Free cash flow | -$85.97M | -$85.03M | -$71.16M | -$65.26M | -$83.30M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IMUX | $7.64 | -2.4% | 68.18K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |